Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT-2102 (olutasidenib) in AML or MDS with IDH1 Mutation
NCT02719574Phase 2Completed
- Sponsor
- Forma Therapeutics, Inc.
- Start
- Apr 2016
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of olutasidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Forma Therapeutics, Inc.. Started Apr 2016; status: completed.
02
Drugs
olutasidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02719574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02719574.